Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without tremelimumab combined with Y-90 SIRT for advanced intrahepatic biliary tract cancer
2018-004778-81Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jul 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in intrahepatic cholangiocarcinoma (ICC) and cholangiocarcinoma (CCA) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective response rate. Started Jul 2019; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2018-004778-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004778-81.